MXD4 and acute myeloid leukemia: To examine whether MXD4 could predict the clinical outcomes of AML patients, we analyzed 288 patients with AML by performing RNA-seq of the leukemic cells isolated from their BM, and the result showed that MXD4 expression is significantly lower in the relapsed patients (Fig. 5h).